SCHEMBL1959095

SCHEMBL1959095

O=S(=O)(c1ccccc1)n1ccc2cc(C(F)(F)F)cnc21

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.57
ALDH1A1 P00352 4/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
HTR6 P50406 9/20 0.46
KMT2A Q03164 3/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 2/20 0.46
TSHR P16473 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
PKM P14618 1/20 0.44
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MET P08581 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500069 0.87 L3MBTL1 (0.57) CYP2C19ALDH1A1LMNAHTTKDM4E
SCHEMBL1960656 0.82 CYP2C19 (0.61) CYP2C19ALDH1A1LMNAHTTHTR6
SCHEMBL1359397 0.80 CYP2C19 (0.61) CYP2C19ALDH1A1LMNAHTTHTR6
SCHEMBL1962403 0.80 CYP2C19 (0.61) CYP2C19ALDH1A1LMNAHTTHTR6
SCHEMBL1958833 0.80 CYP2C19 (0.61) CYP2C19ALDH1A1LMNAHTTMAPT
SCHEMBL10142546 0.80 CYP2C19 (0.61) CYP2C19ALDH1A1LMNAHTTHTR6
SCHEMBL18346376 0.80 CYP2C19 (0.61) CYP2C19ALDH1A1LMNAHTTHTR6
SCHEMBL299699 0.80 CYP2C19 (0.61) CYP2C19ALDH1A1LMNAHTTHTR6
SCHEMBL19747699 0.78 HDAC6 (0.50) CYP2C19
SCHEMBL19746194 0.77 CYP2C19 (0.58) CYP2C19ALDH1A1LMNAHTTHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104926810-B Pyrrolopyridine as kinase inhibitor 阵列生物制药公司 2019-02-19 CN disclosed
CN-102686587-B Azaindole glucokinase activators HOFFMANN LA ROCHE 2015-05-27 CN disclosed
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
CN-102686587-A Azaindole glucokinase activators HOFFMANN LA ROCHE 2012-09-19 CN disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 CYP2C19 792/4885ALDH1A1 769/4885LMNA 4695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.